Literature DB >> 6846493

Contrast sensitivity in albinotic patients.

D S Loshin, R A Browning.   

Abstract

Vertical and horizontal grating contrast sensitivity functions (CSF) were measured on eight albinotic patients. Several of these patients also had CSF measurements performed through their telescopic aids. For all the patients, the horizontal grating CSF was more sensitive than the vertical grafting CSF. Although there are many pathological problems that could result in this sensitivity difference (high astigmatism, neural modification, etc.), we propose that in this case, the nystagmoid eye movements are the main causative factor. Through the telescopic aid, the CSF resolution acuity and peak sensitivity increased. The increase in resolution was somewhat less than would be predicted based on magnification. The increase in sensitivity is believed to be the result of stimulation of more sensitive peripheral retina. This increase in sensitivity is an added benefit to these patients corrected with low vision aids.

Entities:  

Mesh:

Year:  1983        PMID: 6846493     DOI: 10.1097/00006324-198303000-00003

Source DB:  PubMed          Journal:  Am J Optom Physiol Opt        ISSN: 0093-7002


  5 in total

1.  Vision in albinism.

Authors:  C G Summers
Journal:  Trans Am Ophthalmol Soc       Date:  1996

2.  Albinism: particular attention to the ocular motor system.

Authors:  Richard W Hertle
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Jul-Sep

Review 3.  Infantile nystagmus: an optometrist's perspective.

Authors:  Asma Aa Zahidi; J Margaret Woodhouse; Jonathan T Erichsen; Matt J Dunn
Journal:  Clin Optom (Auckl)       Date:  2017-09-25

4.  Effects of spectacles and telescopes on visual function in students with oculocutaneous albinism.

Authors:  Siddeeqa Jhetam; Khathutshelo P Mashige
Journal:  Afr Health Sci       Date:  2020-06       Impact factor: 0.927

5.  Monocular and Binocular Temporal Visual Perception of Infantile Nystagmus.

Authors:  Avital Moshkovitz; Maria Lev; Uri Polat
Journal:  Sci Rep       Date:  2020-03-18       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.